| Bronvermelding: | -TDM monografie SSRI’s NVZA 9www.tdm-monografie.org)
-Hiemke et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. :harmacospychiatry 44:195-235
-Kasper S , Dötsch M , Kick H et al. Plasma concentrations of fl uvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side eff ects . Eur Neuropsychopharmacol 1993 ; 3 :13 – 21
-Schwarzenbach F , Netillard C , Demoly P et al. Antidepressant responseand fluvoxamine plasma concentrations: a pilot study . Pharm World Sci 2003 ; 25 : 27 – 29
-Suhara T , Takano A , Sudo Y et al. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fl uvoxamine using positron emission tomography . Arch Gen Psychiatry 2003 ; 60 : 386 – 391
-Suzuki Y , Fukui N , Sawamura K et al. Concentration-response relationshipfor fluvoxamine using remission as an endpoint: a receiveroperating characteristics curve analysis in major depression . J Clin Psychopharmacol 2008 ; 28 : 325 – 328
-Takano A , Suhara T , Ichimiya T et al. Time course of in vivo 5-HTT transporter occupancy by fluvoxamine . J Clin Psychopharmacol 2006 ; 26 : 188 – 191 |
